Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Evotec AG ( (EVO) ) is now available.
On November 6, 2025, Evotec SE announced the implementation of a share repurchase program, intending to buy back up to 290,000 shares at a total cost of up to EUR 3,000,000. The program, set to run from November 7 to December 17, 2025, aims to convert repurchased shares into American Depositary Shares (ADS) for an employee share program. This strategic move is expected to enhance shareholder value and support employee retention, potentially strengthening Evotec’s market position.
The most recent analyst rating on (EVO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Evotec AG stock, see the EVO Stock Forecast page.
Spark’s Take on EVO Stock
According to Spark, TipRanks’ AI Analyst, EVO is a Neutral.
Evotec AG’s overall stock score is driven by significant financial challenges, including negative profitability and cash flow issues. Technical analysis indicates bearish momentum, while valuation metrics are unattractive due to negative earnings. Despite these challenges, strategic partnerships and cost reduction efforts provide some optimism for future improvement.
To see Spark’s full report on EVO stock, click here.
More about Evotec AG
Evotec SE is a biotechnology company based in Hamburg, Germany, specializing in drug discovery and development services. The company operates in the pharmaceutical and biotechnology industries, providing solutions for research and development processes to accelerate drug discovery and development.
Average Trading Volume: 49,786
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.45B
For detailed information about EVO stock, go to TipRanks’ Stock Analysis page.